Abstract
Bleeding is a common complication during initial induction treatment for acute promyelocytic: leukemia (APL). Administration of all-trans-retinoic acid (ATRA), which is in routine use for APL in the past decade improves the bleeding tendency dramatically. Nevertheless, thrombotic events have still been reported in a small proportion of APL patients treated with ATRA. Here we describe a case of splenic infarction and life threatening thrombosis in a young patient with APL treated with ATRA. We review the relevant literature and discuss the pathophysiology, risk factors and treatment of this complication occurring during therapy, for APL.
| Original language | English |
|---|---|
| Pages (from-to) | 1433-1437 |
| Number of pages | 5 |
| Journal | Leukemia and Lymphoma |
| Volume | 44 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1 Aug 2003 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- APL
- ATRA
- DIC
- Thrombosis
Fingerprint
Dive into the research topics of 'Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver